GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » Cyclically Adjusted FCF per Share

Agios Pharmaceuticals (Agios Pharmaceuticals) Cyclically Adjusted FCF per Share : $-5.28 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-1.774. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-5.28 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-26), Agios Pharmaceuticals's current stock price is $31.50. Agios Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-5.28. Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Agios Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -4.12 -4.68 -5.12

Agios Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.87 -4.97 -5.07 -5.12 -5.28

Competitive Comparison of Agios Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Agios Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.774/131.7762*131.7762
=-1.774

Current CPI (Mar. 2024) = 131.7762.

Agios Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.034 100.560 -0.045
201409 -0.658 100.428 -0.863
201412 -0.264 99.070 -0.351
201503 -0.790 99.621 -1.045
201506 -0.185 100.684 -0.242
201509 -0.750 100.392 -0.984
201512 -0.869 99.792 -1.148
201603 -0.569 100.470 -0.746
201606 4.086 101.688 5.295
201609 -1.361 101.861 -1.761
201612 -1.245 101.863 -1.611
201703 -1.759 102.862 -2.253
201706 -1.284 103.349 -1.637
201709 -1.645 104.136 -2.082
201712 -1.552 104.011 -1.966
201803 -1.803 105.290 -2.257
201806 -1.191 106.317 -1.476
201809 -1.154 106.507 -1.428
201812 -1.293 105.998 -1.607
201903 -1.802 107.251 -2.214
201906 -1.523 108.070 -1.857
201909 -1.490 108.329 -1.812
201912 -1.567 108.420 -1.905
202003 -1.597 108.902 -1.932
202006 -1.043 108.767 -1.264
202009 -1.062 109.815 -1.274
202012 -0.721 109.897 -0.865
202103 -1.751 111.754 -2.065
202106 -1.925 114.631 -2.213
202109 -1.493 115.734 -1.700
202112 -1.632 117.630 -1.828
202203 -1.843 121.301 -2.002
202206 -1.390 125.017 -1.465
202209 -1.302 125.227 -1.370
202212 -1.206 125.222 -1.269
202303 -1.730 127.348 -1.790
202306 -1.200 128.729 -1.228
202309 -1.425 129.860 -1.446
202312 -1.300 129.419 -1.324
202403 -1.774 131.776 -1.774

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Agios Pharmaceuticals  (NAS:AGIO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Agios Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals (Agios Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Executives
Brian Goff director, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens officer: Chief Medical Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James William Burns officer: Chief Legal Officer C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse director C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Tsveta Milanova officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
Cecilia Jones officer: Chief Financial Officer C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Kaye I Foster-cheek director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Washburn Theodore James Jr. officer: Principal Accounting Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey D Capello director C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Catherine E. Owen director 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
David P Schenkein director, 10 percent owner, officer: Chief Executive Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rahul D. Ballal director 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Richa Poddar officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Carman Alenson officer: Principal Accounting Officer 88 SIDNEY STREET, CAMBRIDGE MA 02139

Agios Pharmaceuticals (Agios Pharmaceuticals) Headlines

From GuruFocus

Agios Appoints Jeffrey Capello to Board of Directors

By sperokesalga sperokesalga 04-19-2023

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

By sperokesalga sperokesalga 02-23-2023